Abstract Number: 2000 • ACR Convergence 2020
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Background/Purpose: Prior studies suggest an increased risk of venous thromboembolism (VTE) among patients with rheumatoid arthritis (RA). However, little is known about the comparative risk…Abstract Number: 0211 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients from China, Brazil, and South Korea with Rheumatoid Arthritis Who Have Had Inadequate Response to Conventional Synthetic Disease-modifying Antirheumatic Drugs
Background/Purpose: This Phase 3, randomized, double-blind, placebo (PBO)-controlled study assessed the efficacy and safety of upadacitinib (UPA) in combination with csDMARDs in patients with rheumatoid…Abstract Number: 0450 • ACR Convergence 2020
In Vitro Characterization of Inflammatory Arthritis Associated with Immune Check Point Inhibition
Background/Purpose: During treatment with immune checkpoint inhibitors (ICI) such as the anti-PD-1 antibody pembrolizumab, 2-4% of cancer patients develop inflammatory arthritis as an immune-related adverse…Abstract Number: 0803 • ACR Convergence 2020
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Safety
Background/Purpose: There is limited information on the real-world safety of disease-modifying anti-rheumatic drugs (DMARDs) approved for treating rheumatoid arthritis (RA) in Japan. Using a Japanese…Abstract Number: 0983 • ACR Convergence 2020
Outcomes Following Antimalarial Withdrawal in Patients with Quiescent Systemic Lupus Erythematosus
Background/Purpose: Antimalarial medications (AMs) are central to the management of SLE, affording numerous clinical benefits including the reduction of disease flare. However, little is known…Abstract Number: 1228 • ACR Convergence 2020
Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials
Background/Purpose: Baricitinib (BARI) improved patient-reported outcomes (PROs) in patients with insufficient response or intolerance to ≥1 tumor necrosis factor inhibitors (TNFi) or other biological disease-modifying…Abstract Number: 1718 • ACR Convergence 2020
Impact of Treatments on Radiographic Progression over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort
Background/Purpose: Long-term observational studies on the prediction of structural damage progression (SDP) in rheumatoid arthritis (RA) have mostly considered patients baseline characteristics and have rarely…Abstract Number: 2001 • ACR Convergence 2020
Adverse Effects of Low Dose Methotrexate: Adjudicated Hematologic Outcomes in a Large Randomized Double-blind Placebo-controlled Trial
Background/Purpose: Low dose methotrexate (LD-MTX), a cornerstone in the treatment of rheumatoid arthritis, is associated with a moderately increased risk of anemia and leukopenia, but…Abstract Number: 0213 • ACR Convergence 2020
Sustainability of Response to Upadacitinib as Monotherapy or in Combination Among Patients with Rheumatoid Arthritis and Prior Inadequate Response to Conventional Synthetic DMARDs
Background/Purpose: To assess long-term sustainability of responses to upadacitinib (UPA), a JAK inhibitor, with or without background csDMARD(s) in patients (pts) with rheumatoid arthritis (RA).Methods:…Abstract Number: 0466 • ACR Convergence 2020
Dosage Modification of Immunomodulatory Medications by Rheumatology Patients in New York City During the Peak of the COVID-19 Pandemic
Background/Purpose: Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases living in COVID-19 “hot spots” may have modified their immunomodulatory…Abstract Number: 0806 • ACR Convergence 2020
Identification and Adjustment for Factors Associated with Clinical Response in Rheumatoid Arthritis Clinical Trials to Improve Comparisons of Treatment Efficacy
Background/Purpose: Numerous clinical trials have been published in rheumatoid arthritis (RA), but comparing efficacies of disease-modifying anti-rheumatic drugs (DMARDs) is complicated by a lack of…Abstract Number: 1001 • ACR Convergence 2020
Risk of Malignant Melanoma and Nonmelanoma Skin Cancer in Rheumatoid Arthritis Patients Initiating Methotrexate versus Hydroxychloroquine
Background/Purpose: Previous randomized clinical trials and observational studies have signaled an increased risk of skin cancer in rheumatoid arthritis (RA) patients treated with immunosuppressants such…Abstract Number: 1254 • ACR Convergence 2020
Lack of Efficacy of Early Treatment with Hydroxychloroquine in a Group of Hispanics with Primary Sjögren’s Syndrome
Background/Purpose: Treatment of primary Sjögren’s syndrome (pSS) with hydroxychloroquine (HCQ) has been evaluated in the past but with conflicting results regarding its efficacy. While earlier…Abstract Number: 1746 • ACR Convergence 2020
Association of Obesity with Treatment Response to Methotrexate or Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Background/Purpose: Obesity affects 30-40% of RA patients and is associated with higher clinical disease activity measures and progressive disability. Studies suggest that obesity may be…Abstract Number: 2012 • ACR Convergence 2020
A Phase IIb, Randomized, Double-blind Study in Patients with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Patients with an Inadequate Response to Methotrexate
Background/Purpose: Bruton’s tyrosine kinase (BTK) is involved in multiple signalling pathways potentially implicated in rheumatoid arthritis (RA). Evobrutinib is a highly selective, oral BTK inhibitor.…
ACR Meeting Abstracts